Trusted by the world’s leading institutions
New results provide an important benchmark for researchers, helping to define the most accurate methods for identifying somatic mutations in cancer genomes.
Researchers in Canada and the U.K. have for the first time sequenced and assembled de novo the full genome of a living organism, the bacteria Escherichia Coli, using Oxford Nanopore’s MinIONTM device, a genome sequencer that can fit in the palm of your hand.
Today in the journal Nature prominent researchers from Canada, Europe and the U.S. have made a powerful call to major funding agencies, asking them to commit to establishing a global genomic data commons in the cloud that could be easily accessed by authorized researchers worldwide.
Researchers from the Ontario Institute for Cancer Research (OICR) and the Structural Genomics Consortium (SGC) at the MaRS Discovery District in Toronto have developed a new drug prototype called OICR-9429 and made it freely available to the research community. Already research conducted by international groups using OICR-9429 has shown it to be effective in stopping cancer cell growth in breast cancer cell lines and a specific subtype of leukemia cells.
A study published in the prestigious journal Nature Communications revealed a high degree of heterogeneity in how cancer genome sequencing is done at different institutions across the globe. This result lays the foundation for the coming era of cancer genomics by creating guidelines and providing new tools for achieving higher quality data, for better diagnosis and precision medicine;
New research published in Nature has shown how genome sequencing can be rapidly established to monitor outbreaks.
The International Cancer Genome Consortium (ICGC) announced today that its Data Access Compliance Office (DACO) authorized its 1,000th user, giving them access to the Consortium’s Controlled Access datasets.
The Movember Foundation, the Ontario Institute for Cancer Research (OICR) and Prostate Cancer Canada today announced $3 million in funding for a new Phase III clinical trial to evaluate if magnetic resonance imaging (MRI) can replace the current standard of care to diagnose prostate cancer. The primary objective of the multi-centre trial, called PRECISE, is to determine whether MRI imaging can spare some men from undergoing a biopsy and avoid the possible associated side effects.
Researchers at the Ontario Institute for Cancer Research (OICR) and University Health Network (UHN) in Toronto, along with researchers at the Eastern Virginia Medical School, have created protein signatures that accurately diagnose prostate cancer and can distinguish between patients with aggressive versus non-aggressive disease using a simple urine sample.
Mr. Peter Goodhand, President of The Ontario Institute for Cancer Research (OICR), today announced a new collaborative research study in partnership with Thermo Fisher Scientific and Queen’s University to help bring more targeted diagnosis and treatment to breast cancer patients in the future.
RSS
Medicine keyboard_arrow_right
Sciencekeyboard_arrow_right
Life keyboard_arrow_right
Business keyboard_arrow_right
Journal News keyboard_arrow_right
By Location keyboard_arrow_right
Meetings, Grants, and Events keyboard_arrow_right